Pharmaceutical composition of benzodiazepine compound for nasal mucosa administration and preparation method and application thereof

A technology for mucosal drug delivery and compound, applied in the field of pharmaceutical preparations, can solve the problems of inconvenient medication for patients, high production cost, long production cycle, etc.

Active Publication Date: 2020-06-30
YICHANG HUMANWELL PHARMA
View PDF7 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Compound (R) shown in formula (I) has been reported in Chinese patent CN103202815B 1 and R 2 Both are freeze-dried preparations of salts of methyl), the freeze-drying process has a long preparation cycle, about 5 days a production cycle, the amount of auxiliary materials is large, the industrial production cost is high, and the preparations all need professional medical personnel to inject them, which is very unsafe. convenient
[0004] Most of the current literature reports are that the compound shown in formula (I) is prepared as a freeze-dried powder preparation and then used clinically. The preparation process of this dosage form has a long production cycle and high production costs; clinically, it needs to be temporarily formulated into a solution before it can be used clinically. It is used under the guidance of a professional doctor, and it is often accompanied by injection pain during injection, which makes it inconvenient for patients to take medication and has poor compliance

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition of benzodiazepine compound for nasal mucosa administration and preparation method and application thereof
  • Pharmaceutical composition of benzodiazepine compound for nasal mucosa administration and preparation method and application thereof
  • Pharmaceutical composition of benzodiazepine compound for nasal mucosa administration and preparation method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0069] Compound (R) shown in embodiment 1 formula (I) 1 is methyl, R 2 Prepared for nasal mucosal administration of methyl) benzenesulfonate

[0070] The liposome prescription is as shown in the table,

[0071]

[0072] Preparation Process:

[0073] 1. Microparticle preparation:

[0074] (1) Compound (R) shown in formula (I) 1 is methyl, R 2 Be methyl) besylate as API and Soluplus, magnesium stearate micronization, mix homogeneously, after making physical mixture, add polyethylene glycol P6000.

[0075] (2) Set the extrusion temperature of the twin-screw extruder to 150±10°C, start the screw after rising to the set temperature, add the physical mixture in the step (1) to the extruder, heat-melt, extrude Press and extrude in the form of spherical particles to obtain amorphous particles, which are then micronized to obtain particles with a diameter of less than 150nm.

[0076] 2. Liposome preparation:

[0077] (1) Weigh the microparticles, lecithin, cholesterol, buffe...

Embodiment 2

[0083] Compound (R) shown in embodiment 2 formula (I) 1 is methyl, R 2 Preparation of pharmaceutical composition for ethyl) administration through nasal mucosa

[0084] The liposome prescription is as shown in the table,

[0085]

[0086] Preparation Process:

[0087] 1. Microparticle preparation:

[0088] (1) Compound (R) shown in formula (I) 1 is methyl, R 2 Be ethyl) as API and K30, magnesium stearate micronization, mix uniformly, after making physical mixture, add polyethylene glycol P6000.

[0089] (2) Set the extrusion temperature of the twin-screw extruder to 160±10°C, start the screw after rising to the set temperature, add the physical mixture in the step (1) to the extruder, heat-melt, extrude Press and extrude in the form of spherical particles to obtain amorphous particles, which are then micronized to obtain particles with a diameter of less than 150nm.

[0090] 2. Liposome preparation:

[0091] (1) Weigh the prescribed amount of microparticles, lecithi...

Embodiment 3

[0097] Compound (R) shown in embodiment 3 formula (I) 1 for hydrogen, R 2 Preparation of pharmaceutical composition for nasal mucosa administration

[0098] The liposome prescription is as shown in the table,

[0099]

[0100] Preparation Process:

[0101] 1. Microparticle preparation:

[0102] (1) Compound (R) shown in formula (I) 1 for hydrogen, R 2 For methyl) as API and K90, talcum powder micronization, mix well, after making physical mixture, add polyethylene glycol P2000.

[0103] (2) Set the extrusion temperature of the twin-screw extruder to 150°C, start the screw after rising to the set temperature, add the physical mixture in step (1) to the extruder, heat-melt and extrude, It is extruded in the form of spherical particles to obtain amorphous particles, and then micronized to obtain particles with a diameter of less than 150nm.

[0104] 2. Liposome preparation:

[0105] (1) Weigh microparticles, phosphatidylcholine, cholesterol, buffer, p-phenylenediamine,...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
diameteraaaaaaaaaa
Login to view more

Abstract

The invention discloses a pharmaceutical composition of a benzodiazepine compound for nasal mucosa administration. The pharmaceutical composition comprises a compound shown in a formula (I) or pharmaceutically acceptable salt thereof, a high-molecular dispersion carrier material, a hot-melting protective agent and an optional fluxing agent, wherein the definitions of R1 and R2 in the formula (I) are detailed in the specification. A preparation method of the pharmaceutical composition comprises the following steps of: micronizing the benzodiazepine compound or the pharmaceutically acceptable salt thereof, the high-molecular dispersion carrier material and the hot-melting protective agent, optionally adding the fluxing agent, uniformly mixing to obtain a physical mixture, and then carrying out hot-melting extrusion and micronization to obtain microparticles of the benzodiazepine compound or the pharmaceutically acceptable salt thereof. In addition, the invention also provides the preparation method and application of the pharmaceutical composition. The pharmaceutical composition can be used for treating diseases such as depression and delirium.

Description

technical field [0001] The present invention relates to pharmaceutical preparation technology, more specifically to a kind of benzodiazepine A pharmaceutical composition for administering a class of compounds (that is, a compound represented by formula (I)) through the nasal mucosa, and a preparation method and use thereof. The pharmaceutical composition can be used for the treatment of depression, delirium and other diseases. Background technique [0002] Compound shown in formula (I) (wherein, R 1 selected from hydrogen, methyl, ethyl, isopropyl; R 2 methyl, ethyl) is a new type of benzodiazepine Compounds that are short-acting sedatives. Clinically, it can be used for procedural sedation, induction and maintenance of general anesthesia, sedation of ICU patients, etc. Short-acting sedatives allow the patient to regain consciousness quickly and be discharged from the hospital as soon as possible. In the face of the gradual increase in short-term hospitalization case...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/14A61K31/5517A61K9/127A61P25/24A61P25/00
CPCA61K31/5517A61K9/0043A61K9/146A61K9/127A61P25/24A61P25/00
Inventor 曲龙妹田峦鸢吕金良廖娇金芬郭建锋汪淼李莉娥李仕群符义刚杜文涛李杰杨玉萍张丽娜陈轶苗
Owner YICHANG HUMANWELL PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap